Cost–effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia

References

• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl Cancer Inst. 91(19), 1616–1634 (1999).
   PubMed Web of Science ®Google Scholar
• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am. J. Med. 116(Suppl. 7A), 11S–26S (2004).
   PubMed Web of Science ®Google Scholar
• Jacobsen PB, Thors CL, Cawley M, Ax E, Grendys EC. Relation of decline in hemoglobin to cognitive functioning and fatigue during chemotherapy treatment. Proc. Am. Soc. Clin. Oncol. 21, 386a (2002) (Abstract).
   Google Scholar
• O’Shaughnessy JA, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin. Breast Cancer 5(6), 439–446 (2005).
   PubMedGoogle Scholar
• Bokemeyer C, Oechsle K, Hartmann JT et al. Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br. J. Cancer 87(10), 1066–1071 (2002).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91(12), 2214–2221 (2001).
   PubMed Web of Science ®Google Scholar
• Daly T, Poulsen MG, Denham JW et al. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 68(2), 113–122 (2003).
   PubMed Web of Science ®Google Scholar
• Dunst J, Kuhnt T, Strauss HG et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int. J. Radiat. Oncol. Biol. Phys. 56(3), 778–787 (2003).
   PubMed Web of Science ®Google Scholar
• Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7(6), 492–508 (2002).
   PubMed Web of Science ®Google Scholar
• Macdonald G, Hurman DC. Influence of anaemia in patients with head and neck cancer receiving adjuvant postoperative radiotherapy in the Grampian region. Clin. Oncol. 16(1), 63–70 (2004).
   Web of Science ®Google Scholar
• Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis. Colon Rectum 41(5), 570–585 (1998).
   PubMed Web of Science ®Google Scholar
• Asahara T, Katayama K, Itamoto T et al. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J. Surg. 23(7), 676–680 (1999).
   PubMed Web of Science ®Google Scholar
• Brand A. Immunological aspects of blood transfusions. Transpl. Immunol. 10(2–3), 183–190 (2002).
   PubMed Web of Science ®Google Scholar
• Hyung WJ, Noh SH, Shin DW et al. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann. Surg. Oncol. 9(1), 5–12 (2002).
   PubMed Web of Science ®Google Scholar
• Makino Y, Yamanoi A, Kimoto T et al. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am. J. Gastroenterol. 95(5), 1294–1300 (2000).
   PubMed Web of Science ®Google Scholar
• Pysz M. Blood transfusions in breast cancer patients undergoing mastectomy: possible importance of timing. J. Surg. Oncol. 75(4), 258–263 (2000).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Parrish RS et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol. Obstet. Invest. 56(1), 28–34 (2003).
   PubMed Web of Science ®Google Scholar
• Tachibana M, Tabara H, Kotoh T et al. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Am. J. Gastroenterol. 94(3), 757–765 (1999).
   PubMed Web of Science ®Google Scholar
• van de Watering LMG, Brand A, Houbiers JGA, Klein Kranenbarg WM, Hermans J, van de Velde CJH. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br. J. Surg. 88(2), 267–272 (2001).
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW. USA multicenter clinical trial with recombinant human erythropoietin (Amgen): results in hemodialysis patients. Contrib. Nephrol. 76, 160–165 (1989).
   PubMedGoogle Scholar
• Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. J. Med. 321(3), 158–163 (1989).
   PubMed Web of Science ®Google Scholar
• Fischl M, Galpin JE, Levine JD et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N. Engl. J. Med. 322(21), 1488–1493 (1990).
   PubMed Web of Science ®Google Scholar
• Henry DH, Beall GN, Benson CA et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann. Intern. Med. 117(9), 739–748 (1992).
   PubMed Web of Science ®Google Scholar
• Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2(8517), 1175–1178 (1986).
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br. J. Cancer 84(Suppl. 1), 3–10 (2001).
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 10(11), 2392–2395 (1999).
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Cella D, Chanan-Khan A et al. Cancer and treatment-related anemia. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. V.2. (2004).
   Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. 20(19), 4083–4107 (2002).
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J. Clin. Oncol. 16(10), 3412–3425 (1998).
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19(11), 2875–2882 (2001).
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J. Clin. Oncol. 15(3), 1218–1234 (1997).
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19(11), 2865–2874 (2001).
   PubMed Web of Science ®Google Scholar
• Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 98(5), 1072–1079 (2003).
   PubMed Web of Science ®Google Scholar
• Quirt I, Robeson C, Lau CY et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J. Clin. Oncol. 19(21), 4126–4134 (2001).
   PubMed Web of Science ®Google Scholar
• Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J. Clin. Oncol. 23(12), 2606–2617 (2005).
   PubMed Web of Science ®Google Scholar
• Abels R. Erythropoietin for anaemia in cancer patients. Eur. J. Cancer 29A (Suppl. 2), S2–S8 (1993).
   Google Scholar
• PROCRIT® (epoetin alfa) prescribing information, Ortho Biotech Products L.P., NJ, USA (2005).
   Google Scholar
• Crémieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM. Cost–minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. J. Manag. Care Pharm. 10(6), 531–537 (2004).
   PubMedGoogle Scholar
• Glaspy JA, Jadeja JS, Justice G et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br. J. Cancer 87(3), 268–276 (2002).
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntingt.) 16(Suppl.), 23–29 (2002).
   Google Scholar
• Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br. J. Haematol. 122(3), 394–403 (2003).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl Cancer Inst. 94(16), 1211–1220 (2002).
   PubMed Web of Science ®Google Scholar
• ARANESP® (darbepoetin alfa) prescribing information, Amgen, Inc., CA, USA (2003).
   Google Scholar
• Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97(5), 1312–1320 (2003).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Arena F, Patel D et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 100(4), 859–868 (2004).
   PubMed Web of Science ®Google Scholar
• Kotasek D, Canon J-L, San Miguel J et al. Correction/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized phase 3 active controlled trial. Blood 104(1 Pt 2), 455a (2004) (Abstract).
   Google Scholar
• Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. Oncologist 10(6), 438–448 (2005).
   PubMed Web of Science ®Google Scholar
• Glaspy J, Berg R, Tomita D, Rossi G, Vadhan-Raj S, on behalf of the 20030125 Study Group. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA). J. Clin. Oncol. 23(Suppl.) 760s (2005). Presented at: the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, USA, May 13–17 (2005) (Abstract).
   Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 9(6), 696–707 (2004).
   PubMed Web of Science ®Google Scholar
• Waltzman RJ, Croot C, Williams D. Final hematologic results: epoetin alfa (EPO) 40,000 U QW vs. darbepoetin alfa (DARB) 200 µg Q2W in anemic cancer patients (pts) receiving chemotherapy (CT). J. Clin. Oncol. 23(Suppl.) 736s (2005). Presented at: the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, USA, May 13–17 (2005) (Abstract).
   Google Scholar
• Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a meta-analysis. Clin. Drug Invest. 25(1), 33–48 (2005).
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Fastenau JM, Duh MS, Cremieux P, McKenzie RS, Piech CT. Greater area under the hemoglobin change curve during epoetin alfa treatment is associated with improved patient outcomes. Value Health 7, 317 (2004) (Abstract).
   Google Scholar
• Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr. Med. Res. Opin. 20(3), 381–395 (2004).
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Tchekmedyian NS, Gupta S. Darbepoetin alfa is cost effective compared to epoetin alfa for treatment of anemia in cancer patients receiving chemotherapy. Blood 100(11), 874a (2002) (Abstract).
   Google Scholar
• Rosberg J, Duh MS, Cremieux PY, McKenzie RS, Fastenau JM, Piech CT. Weekly epoetin alfa (EPO QW) for chemotherapy-related anemia is cost-effective compared to darbepoetin alfa administered by every-2-week (DARB Q2W) or front-loading (DARB FL) schedules. Presented at: the International Society for Pharmacoeconomics & Outcomes Research’s (ISPOR) 9th Annual International Meeting, Arlington, VA, USA, May 16–19 (2004) (Abstract).
   Google Scholar
• Frame D, Fastenau J, Piech CT. Cost–effectiveness analysis favors epoetin alfa to front-loaded doses of darbepoetin alfa for treatment of chemotherapy-related anemia. J. Manag. Care Pharm. 10(2), 180 (2004). Presented at: the Academy of Managed Care Pharmacy’s (AMCP) 16th Annual Meeting and Showcase, San Francisco, CA, USA, March 31-April 3 (2004) (Abstract).
   Google Scholar
• Bramley T, Maue S, Floyd K, Fastenau J, Piech CT. Economic comparison of erythropoiesis-stimulating therapies in treating chemotherapy-related anemia in patients with lung cancer. J. Manag. Care Pharm. 9(5), 466 (2003). Presented at: the Academy of Managed Care Pharmacy’s (AMCP’s) 2003 Educational Conference, Montreal, Canada, October 16–18 (2003) (Abstract).
   Google Scholar
• van Hout BA, Gagnon DD. Cost–effectiveness of epoetin alfa (Eprex®) and darbepoetin alfa (Aranesp™) in the treatment of chemotherapy-related anemia. Hematol. J. 5(Suppl. 2) (2004). Presented at: the 9th Congress of the European Hematology Association, Geneva Palexpo, Switzerland, June 10–13 (2004) (Abstract).
   Google Scholar
• Mark TL, McKenzie RS, Piech CT. Better early and overall hematologic outcomes and lower drug cost with epoetin alfa (EPO) compared with darbepoetin alfa (DARB) in patients with chemotherapy-related anemia. J. Manag. Care Pharm. 10(5), 462 (2004). Presented at: the Academy of Managed Care Pharmacy’s (AMCP) 2004 Educational Conference, Baltimore, MD, USA, October 13–16 (2004) (Abstract).
   Google Scholar
• McKenzie RS, Mark TL, Fastenau JM, Piech CT. Clinical and economic benefits of early hemoglobin response following initiation of erythropoietic agents in chemotherapy-related anemia. Presented at: the American Society of Health-System Pharmacists (ASHP) 39th Midyear Clinical Meeting and Exhibits, Orlando, FL, USA, December 5–9 (2004).
   Google Scholar
• Mark TL, McKenzie RS, Piech CT. Better early and overall hematologic outcomes with epoetin alfa (EPO) compared with darbepoetin alfa (DARB) in patients with gynecologic malignancies. Presented at: the Society of Gynecologic Oncologists’ (SGO) 35th Annual Meeting, San Diego, CA, USA, February 7–11 (2004).
   Google Scholar
• Mark TL, McKenzie RS, Piech CT. Epoetin alfa compared with darbepoetin alfa provides significantly higher early hemoglobin rise and overall lower cost in treating chemotherapy-related anemia in patients with breast cancer. Presented at: the American Society of Breast Disease’s (ASBD) 28th Annual Symposium, Boston, MA, USA,April 23–25 (2004).
   Google Scholar
• Mark TL, McKenzie RS, Fastenau JM, Piech CT. Patient benefits of early hemoglobin response following initiation of erythropoietic agents in breast cancer patients with chemotherapy-related anemia. Presented at: the 6th Annual Lynn Sage Breast Cancer Symposium, Chicago, IL, USA, October 28–31 (2004).
   Google Scholar
• McKenzie RS, Mark TL, Piech CT. Better early and overall hematologic outcomes and lower drug cost with epoetin alfa (EPO) compared to darbepoetin alfa (DARB) in colorectal cancer patients. Presented at: the American Society of Clinical Oncology (ASCO) 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, USA,January 22–24 (2004).
   Google Scholar
• McKenzie RS, Mark TL, Piech CT. Evidence-based, comparative assessment of epoetin alfa (EPO) and darbepoetin alfa (DARB) in elderly patients (age ≥ 65) with chemotherapy-related anemia. Presented at: the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) 16th International Symposium on Supportive Care in Cancer, Miami Beach, FL, USA, June 24–27 (2004).
   Google Scholar
• Grad O, Davis J, Vichare R, Fastenau J, Piech CT. Dosing and outcomes study of erythropoiesis-stimulating therapies - D.O.S.E. Support. Care Cancer 12, 419 (2004) (Abstract).
   Google Scholar
• Fahrbach KR, Frame D, Scheye R et al. Comparison of anemia treatment outcomes in patients with cancer receiving epoetin alfa and darbepoetin alfa. Blood 102 (11 part 2), 510b (2003) (Abstract)
   Google Scholar
• Papatheofanis FJ, Fastenau JM, Chiang TH, Suruki RY, Piech CT. Epoetin alfa and darbepoetin alfa anemia treatment outcomes in cancer patients from a Veterans Administration perspective. Value Health 7, 246 (2004). Presented at: the International Society for Pharmacoeconomics & Outcomes Research’s (ISPOR) 9th Annual International Meeting, Arlington, VA, USA, May 16–19 (2004) (Abstract).
   Google Scholar
• Papatheofanis FJ, Fastenau JM, Chiang TH, Suruki RY, Piech CT. Management of chemotherapy-related anemia: a study of epoetin alfa and darbepoetin alfa use in a self-insured managed care organization. J. Manag. Care Pharm. 10(2), 196 (2004). Presented at: the Academy of Managed Care Pharmacy’s (AMCP) 16th Annual Meeting and Showcase, San Francisco, CA, USA, March 31–April 3 (2004) (Abstract).
   Google Scholar
• Killian AD, Gupta V, Goetz A. Inpatient dosing and cost analysis of erythropoietic stimulating therapies (EST) for treatment of chemotherapy-related anemia from community hospitals nationwide. Presented at: the 2004 Annual Meeting of the American College of Clinical Pharmacy,Dallas, TX, USA, October 24–27 (2004).
   Google Scholar
• Decter A, Mody SH, Little J, Duh MS, Watson S, Fastenau J. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. Presented at: the 2004 Annual Meeting of the American College of Clinical Pharmacy, Dallas, TX, USA, October 24–27 (2004).
   Google Scholar
• Sikand H, Greco T, Watson SH, Decter A, Mody SH, Piech CT. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen for oncology patients. Presented at: the American Society of Health-System Pharmacists (ASHP) 39th Midyear Clinical Meeting and Exhibits, Orlando, FL, USA, December 5–9 (2004).
   Google Scholar
• Boccia R, Liu D, Silberstein P et al. Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia. J. Clin. Oncol.23(Suppl.), S761 (2005) (Abstract).
   Google Scholar
• Canon J, Vansteenkiste J, Bodoky G et al. on behalf of the 20030231 Study Group. Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy. J. Clin. Oncol. 23(Suppl.), 799s (2005) (Abstract).
   Google Scholar
• Kotasek D, Steger G, Faught W et al. For the AranespTM 980291 Study Group. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur. J. Cancer 39(14), 2026–2034 (2003).
   PubMed Web of Science ®Google Scholar